This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2009 Apr;55(4):990-1.

doi: 10.1016/j.eururo.2009.01.010.

Words of wisdom. Re: Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma

Robert C Flanigan¹, Anthony Polcari

Affiliations

PMID: 19650236
DOI: 10.1016/j.eururo.2009.01.010

Comment

Words of wisdom. Re: Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma

Robert C Flanigan et al. Eur Urol. 2009 Apr.

. 2009 Apr;55(4):990-1.

doi: 10.1016/j.eururo.2009.01.010.

Authors

Robert C Flanigan¹, Anthony Polcari

Affiliation

¹ Loyola University Medical Center, Maywood, IL 60153, USA. rflanig@lumc.edu

PMID: 19650236
DOI: 10.1016/j.eururo.2009.01.010

Erratum in

Eur Urol. 2009 Nov;56(5):e39. Pulcari, Anthony [corrected to Polcari, Anthony]

No abstract available

PubMed Disclaimer

Comment on

Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma.
Margulis V, Matin SF, Tannir N, Tamboli P, Swanson DA, Jonasch E, Wood CG. Margulis V, et al. J Urol. 2008 Jul;180(1):94-8. doi: 10.1016/j.juro.2008.03.047. Epub 2008 May 15. J Urol. 2008. PMID: 18485389

Publication types

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science